Skip to content
Yog Pharma
CardiovascularAngiotensin II receptor blocker

Losartan Potassium is an angiotensin II receptor blocker indicated for hypertension and diabetic nephropathy in type 2 diabetes. We supply it to US manufacturers of tablets and fixed-dose combinations.

CAS124750-99-8461.0 g/molC22H22ClKN6O
2D structure of Losartan Potassium, shown as the active moiety without counter-ion or water of hydration.

Data from PubChem (CID 11751549) and FDA’s substance registry

CAS number

124750-99-8

Molecular formula

C22H22ClKN6O

Molecular weight

461.0g/mol

FDA UNII

IUPAC name

potassium [2-butyl-5-chloro-3-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol

InChIKey

OXCMYAYHXIHQOA-UHFFFAOYSA-N

Appearance
White to off-white, free-flowing crystalline powder.
Solubility
Freely soluble in water, soluble in alcohols, and slightly soluble in common organic solvents such as acetonitrile and methyl ethyl ketone.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

A tetrazole sartan. Since the 2018 recalls, a nitrosamine risk assessment and an azido impurity statement are standard requests for every source.

On the US market

Reference product
CozaarNDA 020386
Approved ANDAs
16 with a marketed product
Approved forms and strengths
  • Tablet 25 mg, 50 mg, 100 mg
  • Oral suspension 10 mg/mL

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com